Research programme: epidermolysis bullosa therapeutics - InMed Pharmaceuticals

Drug Profile

Research programme: epidermolysis bullosa therapeutics - InMed Pharmaceuticals

Alternative Names: INM-750

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator InMed Pharmaceuticals
  • Class Cannabinoids; Skin disorder therapies
  • Mechanism of Action Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epidermolysis bullosa

Most Recent Events

  • 13 Jun 2017 InMed Pharmaceuticals signs an agreement with Pharmaseed to develop topical formulation of INM 750 for Epidermolysis bullosa
  • 23 Dec 2016 Preclinical trials in Epidermolysis bullosa in Canada (Topical) before December 2016 (InMed pipeline, December 2016)
  • 04 Nov 2015 Pharmacodynamics data from preclinical studies in Epidermolysis bullosa released by InMed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top